XEOMIN
Biological
Merz North America, Inc.
Total Payments
$5.8M
Transactions
28,951
Doctors
8,125
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.2M | 4,997 | 2,558 |
| 2019 | $2.4M | 13,261 | 4,820 |
| 2018 | $2.1M | 10,674 | 4,451 |
| 2017 | $81,993 | 19 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1.7M | 26,974 | 29.2% |
| Unspecified | $1.4M | 475 | 23.5% |
| Consulting Fee | $1.3M | 268 | 23.2% |
| Travel and Lodging | $661,990 | 782 | 11.4% |
| Honoraria | $499,728 | 147 | 8.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $90,604 | 79 | 1.6% |
| Space rental or facility fees (teaching hospital only) | $75,445 | 41 | 1.3% |
| Charitable Contribution | $40,000 | 4 | 0.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $16,495 | 3 | 0.3% |
| Education | $10,604 | 176 | 0.2% |
| Gift | $79.71 | 2 | 0.0% |
Payments by Type
General
$4.4M
28,476 transactions
Research
$1.4M
475 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| STUDY TO INVESTIGATE THE SAFETY AND DURATION OF EFFECT OF DIFFERENT BOTULINUM TOXIN A (NT 201) DOSE GROUPS FOLLOWING THE TREATMENT OF GLABELLAR FROWN LINES | MERZ NORTH AMERICA, INC. | $631,082 | 0 |
| PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF NT 201 IN THE TREATMENT OF LOWER LIMB SPASTICITY CAUSED BY STROKE OR TRAUMATIC BRAIN INJURY IN ADULT SUBJECTS, FOLLOWED BY AN OPEN LABEL EXTENSION WITH OR WITHOUT COMBINED UPPER LIMB TREATMENT | MERZ NORTH AMERICA, INC. | $269,376 | 9 |
| STUDY TO INVESTIGATE THE SAFETY AND DURATION OF EFFECT OF DIFFERENT BOTULINUM TOXIN A (NT 201) DOSE GROUPS FOLLOWING THE TREATMENT OF GLABELLAR FROWN LINES | Merz North America, Inc. | $112,392 | 2 |
| XARA, Paediatric spasticity upper and lower limb | Merz Pharmaceuticals GmbH | $81,993 | 0 |
| SAFETY AND EFFICACY STUDY OF THE SIMULTANEOUS TREATMENT OF UPPER FACIAL LINES (HORIZONTAL FOREHEAD LINES, GLABELLAR FROWN LINES AND LATERAL CANTHAL LINES) IN SUBJECTS WITH MODERATE TO SEVERE UPPER FACIAL LINES (ULTRA I) | MERZ NORTH AMERICA, INC. | $69,932 | 0 |
| PROSPECTIVE, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, DOSE RESPONSE STUDY OF THREE DOSES XEOMIN (INCOBOTULINUMTOXINA, NT 201) FOR THE TREATMENT OF UPPER LIMB SPASTICITY ALONE OR COMBINED UPPER AND LOWER LIMB SPASTICITY IN CHILDREN AND ADOLESCENTS (AGE 2 17 YEARS) WITH CEREBRAL PALSY | MERZ NORTH AMERICA, INC. | $58,237 | 0 |
| PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF NT 201 IN THE TREATMENT OF LOWER LIMB SPASTICITY CAUSED BY STROKE OR TRAUMATIC BRAIN INJURY IN ADULT SUBJECTS, FOLLOWED BY AN OPEN LABEL EXTENSION WITH OR WITHOUT COMBINED UPPER LIMB TREATMENT | Merz North America, Inc. | $37,282 | 11 |
| XEOMIN AND OCCUPATIONAL THERAPY FOR WRITERS CRAMP (PREVIOUSLY IIT 2013 048) | MERZ NORTH AMERICA, INC. | $20,000 | 0 |
| A RETROSPECTIVE ANALYSIS OF FINANCIAL OUTCOME IN MORE THAN 100 PATIENTS SWITCHED FROM BOTOX(ONABOTULINUMTOXINA) TO XEOMIN (INCOBOTULINUMTOXINA) | MERZ NORTH AMERICA, INC. | $17,167 | 0 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF INCOBOTULINUM TOXIN TYPE A FOR THE FUNCTIONAL IMPROVEMENT OF LOWER EXTREMITY SPASTICITY IN PATIENTS WITH MULTIPLE SCLEROSIS (PREVIOUSLY IIT-2011-032) | MERZ NORTH AMERICA, INC. | $14,900 | 0 |
| EVALUATING THE EFFECT OF INCOBOTULINUM TOXIN IN GLABELLA, FOREHEAD, AND CROWS FEET USING HIGH DILUTIONS | MERZ NORTH AMERICA, INC. | $13,819 | 0 |
| ASSESSMENT OF NEED FOR TREATMENT WITH BOTULINUM TOXIN TYPE A IN CERVICAL DYSTONIA PATIENTS | MERZ NORTH AMERICA, INC. | $12,500 | 0 |
| A PLACEBO CONTROLLED, DOUBLE-BLIND, RANDOMIZED, CROSS-OVER PILOT STUDY OF THE EFFICACY AND TOLERABILITY OF INCOBOTULINUM TOXIN A (XEOMIN) AS A TREATMENT FOR FOCAL TASK-SPECIFIC DYSTONIA OF THE MUSICIAN'S HAND (PREVIOUSLY MERZ IIT 2012-046) | MERZ NORTH AMERICA, INC. | $10,000 | 0 |
| EVALUATING COMBINATION TREATMENT APPROACH USING INCOBOTULINUM TOXIN AND COHESIVE POLYDENSIFIED MATRIX HYALURONIC ACID FILLER TO THE PERIOCULAR AREA/CROW'S FEET AND PERIORAL RHYTIDS | MERZ NORTH AMERICA, INC. | $8,129 | 0 |
| COMBINATION THERAPY FOR REJUVENATION OF THE LOWER FACE AND NECK | MERZ NORTH AMERICA, INC. | $4,901 | 0 |
| BOTULINUM TOXIN A FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | MERZ NORTH AMERICA, INC. | $483.60 | 0 |
Top Doctors Receiving Payments for XEOMIN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Loxahatchee, FL | $1.3M | 495 |
| , M.D | Dermatology | San Diego, CA | $202,594 | 72 |
| , M.D | Plastic Surgery | Chicago, IL | $140,263 | 59 |
| , M.D | Plastic Surgery | New York, NY | $137,160 | 56 |
| , M.D | Physical Medicine & Rehabilitation | Houston, TX | $123,831 | 75 |
| , M.D | Dermatology | Coral Gables, FL | $120,073 | 64 |
| , M.D | Specialist | Beverly Hills, CA | $117,628 | 32 |
| , MD | Plastic and Reconstructive Surgery | Chicago, IL | $104,522 | 65 |
| , M.D | Plastic and Reconstructive Surgery | San Francisco, CA | $94,015 | 59 |
| , M.D | Neurology | New York, NY | $91,653 | 83 |
| , M.D | Physical Medicine & Rehabilitation | Houston, TX | $77,249 | 87 |
| , M.D | Physical Medicine & Rehabilitation | Milwaukee, WI | $73,916 | 106 |
| , MD | Specialist | New York, NY | $62,800 | 34 |
| , M.D | Spinal Cord Injury Medicine | Downey, CA | $62,301 | 62 |
| , M.D | Procedural Dermatology | Washington, DC | $60,655 | 58 |
| , MD | Dermatology | Spokane, WA | $56,572 | 41 |
| , M.D | Ophthalmology | Los Angeles, CA | $53,929 | 139 |
| , MD | Plastic and Reconstructive Surgery | New York, NY | $48,554 | 41 |
| , M.D | Spinal Cord Injury Medicine | North Charleston, SC | $38,669 | 28 |
| , MD | Physical Medicine & Rehabilitation | New York, NY | $38,225 | 50 |
| , M.D | Procedural Dermatology | New Orleans, LA | $37,070 | 41 |
| , M.D | Specialist | San Antonio, TX | $33,469 | 22 |
| , MD | Dermatology | Westport, MA | $29,779 | 34 |
| , MD | MOHS-Micrographic Surgery | Birmingham, AL | $28,017 | 15 |
| , MD | Physical Medicine & Rehabilitation | Philadelphia, PA | $27,147 | 9 |
Ad
Manufacturing Companies
- Merz North America, Inc. $4.1M
- MERZ NORTH AMERICA, INC. $1.6M
- Merz Pharmaceuticals GmbH $81,993
Product Information
- Type Biological
- Total Payments $5.8M
- Total Doctors 8,125
- Transactions 28,951
About XEOMIN
XEOMIN is a biological associated with $5.8M in payments to 8,125 healthcare providers, recorded across 28,951 transactions in the CMS Open Payments database. The primary manufacturer is Merz North America, Inc..
Payment data is available from 2017 to 2020. In 2020, $1.2M was paid across 4,997 transactions to 2,558 doctors.
The most common payment nature for XEOMIN is "Food and Beverage" ($1.7M, 29.2% of total).
XEOMIN is associated with 16 research studies, including "STUDY TO INVESTIGATE THE SAFETY AND DURATION OF EFFECT OF DIFFERENT BOTULINUM TOXIN A (NT 201) DOSE GROUPS FOLLOWING THE TREATMENT OF GLABELLAR FROWN LINES" ($631,082).